Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EZH2 shRNA
- Development stage
- Preclinical
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral, Ophthalmic, Intravitreal, Inhalation, Oral, Parenteral
01
Overview
EZH2 shRNA is a short hairpin RNA designed to silence the expression of Enhancer of Zeste Homolog 2 (EZH2), a histone methyltransferase that serves as the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2). By targeting EZH2 mRNA for degradation via the RNA interference (RNAi) pathway, EZH2 shRNA reduces the levels of H3K27me3 (trimethylation of histone H3 lysine 27), thereby modulating gene expression. In research settings, it is utilized to investigate the role of EZH2 in various pathologies, including cancer and cardiovascular diseases like atherosclerosis. Specifically, it has been used to demonstrate that EZH2 knockdown can attenuate endothelial-to-mesenchymal transition (EndMT) in diabetic models, suggesting its potential as a therapeutic target for cardiovascular complications in diabetes.
- Other names
- EZH2 short hairpin RNAEZH-2 short hairpin RNAEZH 2 short hairpin RNAshRNA-EZH2shRNA-EZH-2shRNA-EZH 2
02
Targets
EZH2 (Histone-lysine N-methyltransferase EZH2)
Beyond the preview
Go deeper on EZH2 shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EZH2 shRNA.